The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Budesonide for induction of remission in Crohn's disease
Open accessAbstract
BACKGROUND: Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability. OBJECTIVES: The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn's disease. SEARCH METHODS: The following electronic databases were searched up to June 2014: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD Group Specialised Trial Register, and ClinicalTrials.gov. Reference lists of articles, as well as conference proceedings were manually searched. SELECTION CRITERIA: Randomised controlled trials comparing budesonide to a placebo or active comparator were considered for inclusion. DATA COLLECTION AND ANALYSIS: Two independent investigators reviewed studies for eligibility, extracted the data and assessed study quality. Methodological quality was assessed using the Cochrane risk of bias tool The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. Meta-analysis was performed using RevMan 5.3.5 software. The primary outcome was induction of remission (defined by a Crohn's disease activity index (CDAI) < 150) by week 8 to 16 of treatment. Secondary outcomes included: time to remission, mean change in CDAI, clinical, histological or endoscopic improvement, improvement in quality of life, adverse events and early withdrawal. We calculated the relative risk (RR) and corresponding 95% confidence intervals (CIs) for each dichotomous outcome and the mean difference and corresponding 95% CI for each continuous outcome. Data were analyzed on an intention-to-treat basis. A random-effects model was used for the pooled analyses. The overall quality of the evidence supporting the primary outcomes and selected secondary outcomes was evaluated using the GRADE criteria. MAIN RESULTS: Fourteen studies (1805 patients) were included: Nine (779 patients) compared budesonide to conventional corticosteroids, three (535 patients) were placebo-controlled, and two (491 patients) compared budesonide to mesalamine. Ten studies were judged to be at low risk of bias. Three studies were judged to be at high risk of bias due to open label design. One study was judged to be at high risk of bias due to selective reporting. After eight weeks of treatment, 9 mg budesonide was significantly more effective than placebo for induction of clinical remission. Forty-seven per cent (115/246) of budesonide patients achieved remission at 8 weeks compared to 22% (29/133) of placebo patients (RR 1.93, 95% CI 1.37 to 2.73; 3 studies, 379 patients). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to sparse data (144 events). Budesonide was significantly less effective than conventional steroids for induction of remission at eight weeks. Fifty-two per cent of budesonide patients achieved remission at week 8 compared to 61% of patients who received conventional steroids (RR 0.85, 95% CI 0.75 to 0.97; 8 studies, 750 patients). A GRADE analysis indicated that the overall quality of the evidence for this outcome was moderate due to risk of bias. Budesonide was significantly less effective than conventional steroids among patients with severe disease (CDAI > 300) (RR 0.52, 95% CI 0.28 to 0.95). Studies comparing budesonide to mesalamine were not pooled due to heterogeneity (I(2) = 81%). One study (n = 182) found budesonide to be superior to mesalamine for induction of remission at 8 weeks. Sixty-eight per cent (63/93) of budesonide patients were in remission at 8 weeks compared to 42% (37/89) of mesalamine patients (RR 1.63, 95% CI 1.23 to 2.16). The other study found no statistically significant difference in remission rates at eight weeks. Sixty-nine per cent (107/154) of budesonide patients were in remission at 8 weeks compared to 62% (132/242) of mesalamine patients (RR 1.12, 95% CI 0.95 to 1.32). Fewer adverse events occurred in those treated with budesonide compared to conventional steroids (RR 0.64, 95% CI 0.54 to 0.76) and budesonide was better than conventional steroids in preserving adrenal function (RR for abnormal ACTH test 0.65, 95% CI 0.55 to 0.78). AUTHORS' CONCLUSIONS: Budesonide is more effective than placebo for induction of remission in Crohn's disease. Although short-term efficacy with budesonide is less than with conventional steroids, particularly in those with severe disease or more extensive colonic involvement, the likelihood of adverse events and adrenal suppression with budesonide is lower. The current evidence does not allow for a firm conclusion on the relative efficacy of budesonide compared to 5-ASA products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Variance imputation for overviews of clinical trials with continuous response
Follmann, D., Elliott, P., Suh, I., & Cutler, J. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,385
A method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Faubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Development and Validation of a Pediatric Crohn's Disease Activity Index
Hyams, J. S., Ferry, G. D., Mandel, F. S., Gryboski, J. D., Kibort, P. M., Kirschner, B. S., Griffiths, A. M., Katz, A. J., Grand, R. J., Boyle, J. T., et al. (1991) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.1991.tb10268.x · Cited by 1,050
Self-citationEuropean Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 933
Assessing the Quality of Randomized Trials
Clark, H. D., Wells, G. A., Huët, C., McAlister, F. A., Salmi, L. R., Fergusson, D., & Laupacis, A. (1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00026-4 · Cited by 648
A Comparison of Budesonide with Prednisolone for Active Crohn's Disease
Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., Danielsson, A., Goebell, H., Thomsen, O. O., Lorenz-Meyer, H., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311304 · Cited by 589
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1954) · BMJ · doi:10.1136/bmj.2.4884.375 · Cited by 538
An index of inflammatory activity in patients with Crohn's disease.
van Hees, P. A., van Elteren, P. H., van Lier, H. J., & van Tongeren, J. H. (1980) · Gut · doi:10.1136/gut.21.4.279 · Cited by 331
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Bernstein, C. N., Khan, K. J., Abreu, M. T., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.70 · Cited by 328
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease
Thomsen, O. Ø., Cortot, A., Jewell, D., Wright, J. P., Winter, T., Veloso, F. T., Vatn, M., Persson, T., & Pettersson, E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390603 · Cited by 327
Oral budesonide is as effective as oral prednisolone in active Crohn’s disease
Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.-G., & the Global Budesonide Study Group (1997) · Gut · doi:10.1136/gut.41.2.209 · Cited by 324
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
Hellers, G., Cortot, A., Jewell, D., Leijonmarck, C. E., Löfberg, R., Malchow, H., Nilsson, L.-G., Pallone, F., Pena, S., Persson, T., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70125-3 · Cited by 295
Greenberg, G., Feagan, B., Martin, F., Sutherland, L., Thomson, A., Williams, C., Nilsson, L., & Persson, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8536887 · Cited by 288
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Self-citationNational Cooperative Crohn's Disease Study: Adverse reactions to study drugs
Singleton, J. W., Law, D. H., Kelley, M. L., Mekhjian, H. S., & Sturdevant, R. A. L. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90386-x · Cited by 263
Aminosalicylates for induction of remission or response in Crohn's disease
Lim, W.-C., Wang, Y., MacDonald, J. K., & Hanauer, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008870.pub2 · Cited by 239
Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial
Steinhart, A. H., Feagan, B. G., Wong, C. J., Vandervoort, M., Mikolainis, S., Croitoru, K., Seidman, E., Leddin, D. J., Bitton, A., Drouin, E., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34225 · Cited by 216
Self-citationBudesonide versus prednisone in the treatment of active Crohn's disease
Bar–Meir, S., Chowers, Y., Lavy, A., Abramovitch, D., Sternberg, A., Leichtmann, G., Reshef, R., Odes, S., Moshkovitz, M., Bruck, R., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70254-9 · Cited by 211
Löfberg, R., Rutgeerts, P., Malchow, H., Lamers, C., Danielsson, A., Olaison, G., Jewell, D., Ostergaard Thomsen, O., Lorenz-Meyer, H., Goebell, H., et al. (1996) · Gut · doi:10.1136/gut.39.1.82 · Cited by 209
Budesonide for maintenance of remission in Crohn's disease
Kuenzig, M. E., Rezaie, A., Seow, C. H., Otley, A. R., Steinhart, A. H., Griffiths, A. M., Kaplan, G. G., & Benchimol, E. I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002913.pub3 · Cited by 160
Self-citationSchoon, E. J., Bollani, S., Mills, P. R., Israeli, E., Felsenberg, D., Ljunghall, S., Persson, T., Haptén-White, L., Graffner, H., Bianchi Porro, G., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00662-7 · Cited by 158
Mantzaris, G. J., Christidou, A., Sfakianakis, M. E., Roussos, A., Koilakou, S., Petraki, K., & Polyzou, P. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20777 · Cited by 158
Molecular Mechanisms and Cellular Effects of Glucocorticosteroids
Barnes, P. J. (2005) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2005.05.003 · Cited by 153
National Cooperative Crohn's Disease Study: Study design and conduct of the study
Winship, D. H., Summers, R. W., Singleton, J. W., Best, W. R., Becktel, J. M., Lenk, L. F., & Kern, F. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90383-4 · Cited by 144
Danielsson, Å., Hellers, G., Lyrenäs, E., Löfberg, R., Nilsson, A. M., Olsson, O., Olsson, S., Persson, T., Salde, L., Næsdal, J., et al. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528708991947 · Cited by 132
Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study
Ferguson, Campieri, M., Doe, Persson, Nygård, & THE GLOBAL BUDESONIDE STUDY GROUP (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00285.x · Cited by 124
Tremaine, W. J., Hanauer, S. B., Katz, S., Winston, B., Levine, J. G., Persson, T., & Persson, A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05835.x · Cited by 121
Sandborn, W. J., Löfberg, R., Feagan, B. G., Hanauer, S. B., Campieri, M., & Greenberg, G. R. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41992.x · Cited by 119
Systematic review: the effectiveness of budesonide therapy for Crohn's disease
Kane, S. V., Schoenfeld, P., Sandborn, W. J., Tremaine, W. J., Hofer, T. P., & Feagan, B. G. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01289.x · Cited by 116
Budesonide for induction of remission in Crohn's disease
Seow, C. H., Benchimol, E. I., Griffiths, A. M., Otley, A. R., & Steinhart, A. H. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000296.pub3 · Cited by 115
Self-citationCortot, A., Colombel, J.-F., Rutgeerts, P., Lauritsen, K., Malchow, H., Hämling, J., Winter, T. A., Gossum, A. V., Persson, T., & Pettersson, E. (2001) · Gut · doi:10.1136/gut.48.2.186 · Cited by 110
Aminosalicylates for induction of remission or response in Crohn's disease
Lim, W. C., & Hanauer, S. B. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008870 · Cited by 110
Escher, J. C. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200401000-00008 · Cited by 109
Groß, V., Andus, T., Caesar, I., Bischoff, S. C., Lochs, H., Tromm, A., Schulz, H. J., Bär, U., Weber, A., Gierend, M., et al. (1996) · PubMed · Cited by 108
Gross, V., Andus, T., Ecker, K. W., Raedler, A., Loeschke, K., Plauth, M., Rasenack, J. W. F., Weber, A., Gierend, M., Ewe, K., et al. (1998) · Gut · doi:10.1136/gut.42.4.493 · Cited by 107
Budesonide in the treatment of Crohn’s disease: a meta‐analysis
Papi, C., Luchetti, R., Gili, L., Montanti, S., Koch, M., & Capurso, L. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00867.x · Cited by 106
Spencer, C. M., & McTavish, D. (1995) · Drugs · doi:10.2165/00003495-199550050-00006 · Cited by 104
Tromm, A., Bunganič, I., Tomsová, E., Tulassay, Z., Lukáš, M., Kykal, J., Bátovský, M., Fixa, B., Gabalec, L., Safadi, R., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.11.004 · Cited by 93
Cino, M., & Greenberg, G. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05609.x · Cited by 86
A Comparison of Budesonide and Prednisone for the Treatment of Active Pediatric Crohn Disease
Levine, A., Weizman, Z., Broide, E., Shamir, R., Shaoul, R. R., Pacht, A., Dinari, G., On, A., Weiss, B., & Bujanover, Y. (2003) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200302000-00017 · Cited by 83
Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide
Fedorak, R. N., & Bistritz, L. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.08.009 · Cited by 82
Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial
Hanauer, S. B., Sandborn, W. J., Persson, A., & Persson, T. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02338.x · Cited by 80
Oral budesonide in active Crohn's disease
Löfberg, R., Danielsson, A., & Salde, L. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00141.x · Cited by 56
Suzuki, Y., Motoya, S., Takazoe, M., Kosaka, T., Date, M., Nii, M., & Hibi∥, T. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.06.006 · Cited by 55
Controlled Ileal Release Budesonide in Pediatric Crohn Disease: Efficacy and Effect on Growth
Kundhal, P. S., Zachos, M., Holmes, J. L., & Griffiths, A. M. (2001) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2001.tb07405.x · Cited by 53
Self-citationBudesonide for induction of remission in Crohn's disease
Otley, A. R., & Steinhart, A. H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000296.pub2 · Cited by 53
Self-citationDignass, A. U., Stoynov, S. G., Dorofeyev, A. E., Grigorieva, G. A., Tomsová, E., Altorjay, I., Tuculanu, D., Bunganič, I., Pokrotnieks, J., Kupčinskas, L., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.01.021 · Cited by 48
Quality of Life Rapidly Improves with Budesonide Therapy for Active Crohnʼs Disease
Irvine, E. J., Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A. B. R., Nilsson, L.-G., & Persson, T. (2000) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780060305 · Cited by 47
Levine, A., Broide, E., Stein, M., Bujanover, Y., Weizman, Z., Dinari, G., Pacht, A., Branski, D., & Zahavi, I. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.119992 · Cited by 39
Mantzaris, G. J., Petraki, K., Sfakianakis, M. E., Archavlis, E. J., Christidou, A., Chadio-Iordanides, H., & Triadaphyllou, G. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1053/cgh.2003.50015 · Cited by 39
Levine, A., Kori, M., Dinari, G., Broide, E., Shaoul, R. R., Yerushalmi, B., On, A., Bujanover, Y., Proels, M., & Greinwald, R. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20881 · Cited by 33
Lundin, P., Naber, A. H. J., Nilsson, M., & Edsbäcker, S. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00910.x · Cited by 32
Budesonide for Inflammatory Bowel Disease -- Is It a Magic Bullet?
Sachar, D. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311311 · Cited by 32
Budesonide for maintenance of remission in Crohn's disease
Simms, L., & Steinhart, A. H. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002913 · Cited by 32
Self-citationHerfarth, H. H., Gross, V., Andus, T., Caesar, I., Vogelsang, H., Adler, G., Malchow, H. A., Petri, A., Gierend, M., & Sch�lmerich, J. (2004) · International Journal of Colorectal Disease · doi:10.1007/s00384-003-0529-5 · Cited by 30
Conventional treatment of Crohn's disease: Objectives and outcomes
Rutgeerts, P. J. (2001) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780070503 · Cited by 27
Budesonide and Mesalazine in Active Crohn's Disease: A Comparison of The Effects on Quality of Life
Thomsen, O. Ø., Cortot, A., Jewell, D. P., WRIGHT, J. P., Winter, T. A., Veloso, F. T., Vatn, M., Persson, T., & Pettersson, E. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)04106-5 · Cited by 25
Green, J. R. B., Lobo, A., Giaffer, M. H., Travis, S. P. L., Watkins, H. C., & THE FREEDOM INVESTIGATOR GROUP (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01055.x · Cited by 25
Infliximab for the Treatment of Crohn'S Disease: Review and Indications for Clinical Use in Canada
Panaccione, R. (2001) · Canadian Journal of Gastroenterology · doi:10.1155/2001/490921 · Cited by 20
Treatment of Crohn's Disease at the Turn of the Century
Bickston, S. J., & Cominelli, F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390610 · Cited by 20
Maintenance Therapy in Crohn's Disease
Steinhart, H. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/480782 · Cited by 18
Metaanálisis sobre la efectividad de la budesonida en la enfermedad inflamatoria intestinal
Nos, P., Ponce, J. D. C., Hinojosa, J., & Gomollón, F. (2001) · Medicina Clínica · doi:10.1016/s0025-7753(01)71716-2 · Cited by 18
Gelbmann, C. M., Rogler, G., Gierend, M., Groß, V., Schölmerich, J., & Andus, T. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200112000-00006 · Cited by 17
The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
Breslin, N., & Sutherland, L. (1998) · PubMed · Cited by 14
10 Adjuvant post-operative therapy
Leiper, K., London, I., & Rhodes, J. M. (1998) · Baillière s Clinical Gastroenterology · doi:10.1016/s0950-3528(98)90092-6 · Cited by 13
Steroid-Dependent Crohn’s Disease
Sandborn, W. J. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/513130 · Cited by 13
The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
Rutgeerts, P. (1998) · Mediators of Inflammation · doi:10.1080/09629359891036 · Cited by 10
The Use of Budesonide in the Treatment of Active Crohn's Disease Is Good Clinical Practice
Rutgeerts, P. J. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200102000-00010 · Cited by 9
Treatment of Crohn's disease with budesonide: this rose still has thorns!
Valentine, J. F. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)03949-7 · Cited by 3
Budesonide: Is No Evidence of a Difference the Same as Evidence of No Difference?
Sutherland, L. R. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200102000-00009 · Cited by 3
Stange, E. F. (1999) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/bf03042032 · Cited by 2
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
Metadata
- Authors
- Rezaie, A., Kuenzig, M. E., Benchimol, E. I., Griffiths, A. M., Otley, A. R., Steinhart, A. H., Kaplan, G. G., & Seow, C. H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-06-03
- Volume
- 2015
- Issue
- 6
- Pages
- CD000296-CD000296
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1774343840
- Cited by
- 260
- References
- 87
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.